https://doi.org/10.4081/reumatismo.2016.917

A case of mandible Paget’s disease of the bone treated with intravenous neridronate

Vol. 68 No. 3 (2016)
Submitted: 8 August 2016
Accepted: 24 October 2016
Published: 16 December 2016
Paget’s disease of the bone, neridronate, mandible.
Abstract Views: 1707
PDF: 977
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

A. Fassio
angelo.fassio@yahoo.it
Unit of Rheumatology, University of Verona, Italy.
L. Idolazzi
Unit of Rheumatology, University of Verona, Italy.
M. Rossini
Unit of Rheumatology, University of Verona, Italy.
O. Viapiana
Unit of Rheumatology, University of Verona, Italy.
D. Gatti
Unit of Rheumatology, University of Verona, Italy.
Paget’s disease of bone (PDB) is a focal disorder of osteoclasts, leading to chaotic bone remodelling, and it is characterized by the presence of focal areas of excessive bone formation alongside with areas of focal bone resorption. The typical radiographic feature is the cotton wool appearance. To date, bisphosphonates are the mainstay of the treatment. We hereby report the case of a young woman presenting with mandible PDB, with a relevant diagnostic delay and mistakenly treated for five years with chronic oral corticosteroids. After our evaluation, the patient received treatment with intravenous neridronate (an amino-bisphosphonate licensed in Italy for the treatment of this disease), with achievement of clinical remission.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Fassio, A., Idolazzi, L., Rossini, M., Viapiana, O., & Gatti, D. (2016). A case of mandible Paget’s disease of the bone treated with intravenous neridronate. Reumatismo, 68(3), 154–158. https://doi.org/10.4081/reumatismo.2016.917

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Similar Articles

<< < 46 47 48 49 50 51 52 53 54 55 > >> 

You may also start an advanced similarity search for this article.